Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases
- PMID: 28058009
- PMCID: PMC5175241
- DOI: 10.3748/wjg.v22.i47.10275
Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases
Abstract
Proteases, enzymes catalyzing the hydrolysis of peptide bonds, are present at high concentrations in the gastrointestinal tract. Besides their well-known role in the digestive process, they also function as signaling molecules through the activation of protease-activated receptors (PARs). Based on their chemical mechanism for catalysis, proteases can be classified into several classes: serine, cysteine, aspartic, metallo- and threonine proteases represent the mammalian protease families. In particular, the class of serine proteases will play a significant role in this review. In the last decades, proteases have been suggested to play a key role in the pathogenesis of visceral hypersensitivity, which is a major factor contributing to abdominal pain in patients with inflammatory bowel diseases and/or irritable bowel syndrome. So far, only a few preclinical animal studies have investigated the effect of protease inhibitors specifically on visceral sensitivity while their effect on inflammation is described in more detail. In our accompanying review we describe their effect on gastrointestinal permeability. On account of their promising results in the field of visceral hypersensitivity, further research is warranted. The aim of this review is to give an overview on the concept of visceral hypersensitivity as well as on the physiological and pathophysiological functions of proteases herein.
Keywords: Inflammatory bowel diseases; Irritable bowel syndrome; Protease inhibitors; Proteases; Proteinase-activated receptors; Visceral hypersensitivity; Visceral pain.
Conflict of interest statement
Conflict-of-interest statement: No potential conflicts of interest.
Figures



Similar articles
-
Protease-activated receptor signaling in intestinal permeability regulation.FEBS J. 2020 Feb;287(4):645-658. doi: 10.1111/febs.15055. Epub 2019 Sep 23. FEBS J. 2020. PMID: 31495063 Review.
-
Role for protease activity in visceral pain in irritable bowel syndrome.J Clin Invest. 2007 Mar;117(3):636-47. doi: 10.1172/JCI29255. Epub 2007 Feb 15. J Clin Invest. 2007. PMID: 17304351 Free PMC article.
-
Prostaglandin E2, Produced by Mast Cells in Colon Tissues From Patients With Irritable Bowel Syndrome, Contributes to Visceral Hypersensitivity in Mice.Gastroenterology. 2020 Jun;158(8):2195-2207.e6. doi: 10.1053/j.gastro.2020.02.022. Epub 2020 Feb 19. Gastroenterology. 2020. PMID: 32084424 Free PMC article.
-
Visceral hypersensitivity in irritable bowel syndrome.J Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:119-21. doi: 10.1111/j.1440-1746.2011.06640.x. J Gastroenterol Hepatol. 2011. PMID: 21443723
-
Altered protease signalling in the gut: a novel pathophysiological factor in irritable bowel syndrome.Neurogastroenterol Motil. 2008 Aug;20(8):853-6. doi: 10.1111/j.1365-2982.2008.01155.x. Neurogastroenterol Motil. 2008. PMID: 18710475 Review. No abstract available.
Cited by
-
The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model.Front Pharmacol. 2021 Jun 24;12:682065. doi: 10.3389/fphar.2021.682065. eCollection 2021. Front Pharmacol. 2021. PMID: 34248633 Free PMC article.
-
PPARγ activation attenuates neonatal CRD-induced visceral pain sensitization and anxiety in male rats by alleviating oxidative stress.BMC Gastroenterol. 2025 Jan 20;25(1):22. doi: 10.1186/s12876-025-03618-3. BMC Gastroenterol. 2025. PMID: 39833676 Free PMC article.
-
Enzyme-Based Anti-Inflammatory Therapeutics for Inflammatory Diseases.Pharmaceutics. 2025 May 2;17(5):606. doi: 10.3390/pharmaceutics17050606. Pharmaceutics. 2025. PMID: 40430897 Free PMC article. Review.
-
Electroacupuncture Zusanli (ST36) Relieves Somatic Pain in Colitis Rats by Inhibiting Dorsal Root Ganglion Sympathetic-Sensory Coupling and Neurogenic Inflammation.Neural Plast. 2023 Mar 2;2023:9303419. doi: 10.1155/2023/9303419. eCollection 2023. Neural Plast. 2023. PMID: 36910013 Free PMC article.
-
The role of the gut microbiome in disorders of gut-brain interaction.FEBS J. 2025 Mar;292(6):1357-1377. doi: 10.1111/febs.17200. Epub 2024 Jun 23. FEBS J. 2025. PMID: 38922780 Review.
References
-
- Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429. - PubMed
-
- Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313:949–958. - PubMed
-
- Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Epub ahead of print. - PubMed
-
- Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–217. - PubMed
-
- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721.e4. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous